Management of severe atopic dermatitis in children

Journal of Drugs in Dermatology

Volumn 11, Issue 10, 2012, Pages 1158-1165

  Tan, Ainah U ^a   Gomzalez, Mercedes E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; HYPOCHLORITE SODIUM; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; RECOMBINANT GAMMA INTERFERON; RITUXIMAB;

ARTICLE; ATOPIC DERMATITIS; BATH; BIOLOGICAL THERAPY; CHILD CARE; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FATIGUE; HEADACHE; HUMAN; IMMUNOPATHOGENESIS; NAUSEA; OSTEOPOROSIS; PARESTHESIA; QUALITY OF LIFE; SIDE EFFECT; SKIN INFECTION; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE; ULTRAVIOLET RADIATION; VOMITING; WEIGHT GAIN;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BATHS; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DERMATITIS, ATOPIC; DISINFECTANTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; METHOTREXATE; MYCOPHENOLIC ACID; SODIUM HYPOCHLORITE; ULTRAVIOLET THERAPY;

EID: 84868610291     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131:67-73.
2. Williams H, Stewart A, von Mutius, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121:947-954.
3. Carroll CL, Balkrishnan R, Feldman SR et al. The Burden of Atopic dermatitis: Impact on the Patient, Family, and Society. Pediatr Dermatol. 2005;22:192-199. (Pubitemid 40741251)
4. O'Connell EJ. The burden of atopy and asthma in children. Allergy. 2004;59(78):7-11. (Pubitemid 39005839)
5. Irvine AD, Mclean WHI. Breaking the (Un)Sound Barrier: Filaggrin Is a Major Gene for Atopic Dermatitis. J Invest Dermatol. 2006;126:1200-1202. (Pubitemid 43997892)
6. Kunz B, Oranje AP, et al Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10-19. (Pubitemid 27326702)
7. Smith SD, Hong E, Fearns S, et al. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol. 2010;51(3):168-74.
8. Paller AA, Eichenfield LE, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122:e1210-e1218.
9. Devillers AC, Oranje AP. Wet-Wrap Treatment in Children with Atopic Dermatitis: A Practical Guideline. Pediatric Dermatol. 2012;29(1):24-27.
10. Devillers AC, Oranje AP. Efficay and safety of wet-wrap dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006;154:579-585 (Pubitemid 43374079)
11. Huang JT, Abrams M, Tlougan B, et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity Pediatrics. 2009;123(5):e808-e814.
12. Atherton DJ, Carabott F, Glover MT, et al. The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. Br J Dermaol. 1988;118:791-795.
13. Collins P, Ferguson J. Narrowband (TL-01) air-conditioned phototherapy for atopic eczema in children. Br J Dermatol. 1995;133:653-67.
14. Tay YK, Morelli, JG, Weston WL. Experience with UVB Phototherapy in Children. Pediatr Dermatol. 1996;13(5):406-409. (Pubitemid 26326174)
15. Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol. 2006;31(2):196-199.
16. Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28-33. (Pubitemid 46006361)
17. Tan E, Lim D, Rademaker M. Narrowband UVB phototherapy in children: A New Zealand experience. Australas J Dermatol. 2010;51:268-273.
18. Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. 2011;25(6):727-9
19. Pathak MA JK, Szabo G, Fitzpatrick TB. Sun light and melanin pigmentation. In: Smith K ed. Photochemical and Photobiological Reviews. Plenum, New York, 1976: 211-239.
20. Walters IB, Ozawa M, Cardinale I et al. Narrowband (312nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 trascripts: differential regulation of cytokines at the single-cell level. Arch Dermatol. 2003;139:155-61. (Pubitemid 36216253)
21. Flurhr JW, Gloor M. The antimicrobial effect of narrowband UVB (313) and UVA1(345-440 nm) radiation in vitro. Photodermatol Photoimmunol Photomed. 1997;13:197-201. (Pubitemid 28116611)
22. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol. 2005;44:355-60. (Pubitemid 40691978)
23. Schmitt J, Schakel K, Folster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162(3):661-668.
24. Ring J, Alomar A, Beiber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176-1193.
25. Madan V, Griffiths CEM. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20(4):239-250. (Pubitemid 350029313)
26. Griffiths CEM, Katsambas A, Dijkman BAC, et al. Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;(155 Suppl)2:1-16. (Pubitemid 43855773)
27. Granlund H. Treatment of childhood eczema. Paediatr Drugs. 2002;4(11):729-735. (Pubitemid 35316392)
28. Bonguniewicz M, Schmid-Grendelmeier P, Leung DYM. Atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):40-43. (Pubitemid 43946486)
29. Schmitt J, Schakel K, Schmitt N, et al. Systemic treatment of severe atopic eczema: a systematic review. Acta Dermatol Venereol. 2007;87(2):100-111. (Pubitemid 46521989)
30. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in severe childhood atopical dermatitis: a multicentre study. J Am Acad Dermatol. 1996;34(6):1016-1021. (Pubitemid 26170768)
31. Leonardi S, Marchese G, Rotolo N, Miraglia Del Giudice M, La Rosa M. Cyclosporin is safe and effective in severe atopic dermatitis of childhood: Report of three cases. Minerva Pediatr. 2004;56(2):231-237. (Pubitemid 38843263)
32. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol. 1996;135(Suppl 48):21-24. (Pubitemid 26294726)
33. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69(3):297-306
34. Harper JI, Ahmed IA, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142:52-58. (Pubitemid 30074470)
35. Bunikowski R, Staab D, Kussebi F, et al. Low-dose cyclosporin A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pediatr Allergy Immunol. 2001; 12:216-223. (Pubitemid 32768762)
36. Berth-Jones J, Graham-Brown RAC, Marks R, et al. Long-term efficacy and safety of cyclosporine in severe adult atopic dermatitis. Br J Dermatol. 1997;136:76-81. (Pubitemid 27016179)
37. Liu H, Wong C. In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch Dermatol Res. 1997;289:94-97. (Pubitemid 27075574)
38. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol. 2001;26:69-75.
39. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131:193-7
40. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839-846. (Pubitemid 43363371)
41. Murphy LA, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol. 2002;147(2):308-315.
42. Murphy LA, Atherton D. Azathioprine as a Treatment for Severe Atopic Eczema in Children with a Partial Thiopurine Methyl Transferase (TPMT) Deficiency. Pediatr Dermatol. 2003;20(6):531-534. (Pubitemid 38021322)
43. Hon KLE, Ching G, Leung TF, Chow CM, Lee KC, Cheung P. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Derm Treat. 2009;20;3;141-145.
44. Martel RM, Melwani P, Islas D, Penate Y, Borrego L. Safety of Azathioprine Therapy Adjusted to Thiopurine Methyltransferase Activity in the Treatment of Infantile Atopic Dermatitis. Report on 7 Cases. Actas Dermosifiliogr. 2010;101(5):415-420.
45. Waxweiler WT, Agans R, Morrell DS. Systemic Treatment of Pediatric Atopic Dermatitis with Azathioprine and Mycophenolate Mofetil. Pediatr Dermatol. 2011;28(6):689-694.
46. Caufield M, Tom WL. Oral Azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2012. [Epub ahead of print]
47. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol. 2011;165:711-734.
48. Neuber K, Schwartz I, Itschert G et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143:385-91. (Pubitemid 30650410)
49. Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32:23-27. (Pubitemid 46006360)
50. Grundmann-Kollmann M, Podda M, Ochsendorf F et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol. 2001;137:870-873. (Pubitemid 32641646)
51. Heller M, Shin HT, Orlow SJ, et al. Mycophenolate mophetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol. 2007;157:127-132. (Pubitemid 46934265)
52. Jeffes EWB III, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis. Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183-188.
53. Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266-273. (Pubitemid 34716307)
54. Lyakhovitsky A, Barsilai A, Heyman R, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24:43-44
55. Schram ME, Roekevisch E, Geertruida Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353-359.
56. Weatherhead SC, Wahie S, Reynolds NJ et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2): 346-351. (Pubitemid 46095964)
57. Goujon C, Berard F, Dahel K, A et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol. 2006;16(2):155-158.
58. de Jager ME, de Jong EMGJ, van de Kerkhof, PCM, et al. Efficacy and safety of treatments for childhood psoriasis: A systematic literature review. J Am Acad Dermatol. 2010;62:1013-1030.
59. Christen-Zaech, S, Hakim MD, Afsar FS, et al. Pediatric morphea (localized scleroderma): Review of 136 patients. J Am Acad Dermatol. 2008;59(3):385-396.
60. Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea) J Am Acad Dermatol. [in press]
61. Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: Review of the dermatologic and rheumatologic literature. J Am Acad Dermatol. 2005;52:316-340.
62. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005; 53:652-659. (Pubitemid 41399934)
63. Wolverton S. 2007. Comprehensive dermatologic drug therapy. 2nd ed. Philadelphia: Elsevier.
64. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child. 1994;70:335-336. (Pubitemid 24174751)
65. Huang JL, Lee WY, Chen LC, et al. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1, and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol. 2000;84:345-352.
66. Ozen A, Baris S, Karakoc Aydiner E, Yucelten D, Nadir Bahceciler N. Experience with intravenous immunoglobulin in severe childhood atopic dermatitis. Allergol Immunopathol (Madr). 2012;40(2):131-133.
67. Turner PJ, Kakakios A, Wong L, et al. Intravenous Immunoglobulin to Treat Severe Atopic Dermatitis in Children: A Case Series Pediatr Dermatol. 2012;29(2):177-181.
68. Jee SJ, Kim JH, Baek HS, et al. Long-term Efficacy of Intravenous Immunoglobulin Therapy for Moderate to Severe Childhood Atopic Dermatitis. All Asthma Immunol Res. 2011;3(2):89-95.
69. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol. 200;142:551-554.
70. Schneider LC, Baz Z, Zarcone C, et al. Long-term therapy with recombinant interferon-gamma (rIFN-) for atopic dermatitis. Ann Allergy Asthma Immunol. 1998;80:263-268. (Pubitemid 28145315)
71. Frisch S, Siegfried EC. The Clinical and Therapeutic Challenge of Eczema Herpeticum. Pediatr Dermatol. 2011;28(1):46-52.
72. España A, Ornilla E, Panizo C. Rituximab in Dermatology. Actas Dermosifiliogr. 2012; epub
73. Simon D, Holi S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122-8.
74. Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol. 2011;29:209-219.
75. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338-340. (Pubitemid 40979597)
76. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54:68-72. (Pubitemid 41832460)
77. Heil PM, Maurer D, Klein B, et al. Omaizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebocontrolled and double blind pilot study. J Ger Society Dermatol. 2010;8:990-998.
78. Turner MJ, Travers JB, Kaplan MH. T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol. 2012;11(10), in press.